Contrasting US Stem Cell (USRM) & Dyadic International (DYAI)

US Stem Cell (OTCMKTS:USRM) and Dyadic International (OTCMKTS:DYAI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for US Stem Cell and Dyadic International, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
US Stem Cell 0 0 0 0 N/A
Dyadic International 0 0 1 0 3.00

Risk and Volatility

US Stem Cell has a beta of 6.04, suggesting that its share price is 504% more volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.

Profitability

This table compares US Stem Cell and Dyadic International’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
US Stem Cell -21.01% N/A -66.41%
Dyadic International -841.68% N/A N/A

Earnings & Valuation

This table compares US Stem Cell and Dyadic International’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
US Stem Cell $5.52 million 1.70 -$3.48 million N/A N/A
Dyadic International $760,000.00 72.05 -$2.14 million ($0.17) -12.06

Dyadic International has lower revenue, but higher earnings than US Stem Cell.

Institutional & Insider Ownership

0.0% of Dyadic International shares are owned by institutional investors. 16.7% of US Stem Cell shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Dyadic International beats US Stem Cell on 5 of the 9 factors compared between the two stocks.

About US Stem Cell

U.S. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Its lead product candidates include MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells or cells from a patient's body for enhancing cardiac function in chronic heart failure patients; and AdipoCell, a patient-derived cell therapy for the treatment of acute myocardial infarction, chronic heart ischemia, and lower limb ischemia. The company's product development pipeline includes MyoCell SDF-1, an autologous muscle-derived cellular therapy for improving cardiac function in chronic heart failure patients. It is also developing MyoCath, a deflecting tip needle injection catheter that is used to inject cells into cardiac tissue in therapeutic procedures to treat chronic heart ischemia and congestive heart failure. In addition, the company provides physician and patient based regenerative medicine/cell therapy training services, cell collection, and cell storage services; and cell collection and treatment kits for humans and animals, as well operates a cell therapy clinic. The company was formerly known as Bioheart, Inc. and changed its name to U.S. Stem Cell, Inc. in October 2015. U.S. Stem Cell, Inc. was founded in 1999 and is headquartered in Sunrise, Florida.

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corp. to express two therapeutic compounds using C1 production platform; and the Sanofi-Aventis Deutschland GmbH to express the potential of its C1 technology to produce various types of therapeutic compounds for manufacturing protein-based vaccine and biologic drugs; and research collaboration with global biotech company to explore the potential of its C1 technology to produce an active moiety. The company was founded in 1979 and is headquartered in Jupiter, Florida.

Receive News & Ratings for US Stem Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for US Stem Cell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply